Literature DB >> 27220737

Short-term efficacy of treating hepatitis B virus-related acute-on-chronic liver failure based on cold pattern differentiation with hot herbs: A randomized controlled trial.

Yu-Ming Guo1, Feng-Yi Li2, Man Gong3, Lin Zhang4, Jia-Bo Wang1, Xiao-He Xiao5, Jun Li6, Yan-Ling Zhao3, Li-Fu Wang3, Xiao-Feng Zhang3.   

Abstract

OBJECTIVE: To evaluate the clinical efficacy and safety of Yinchen Zhufu Decoction (, YCZFD) in the treatment of acute-on-chronic liver failure caused by hepatitis B virus (HBV-ACLF) with cold pattern in Chinese medicine (CM).
METHODS: This is a multi-center randomized controlled trial of integrative treatment of CM and Western medicine (WM) for the management of HBV-ACLF patients. A total of 200 HBV-ACLF patients with cold pattern were equally randomly assigned to receive YCZFD and WM (integrative treatment) or WM conventional therapy alone respectively for 4 weeks. The primary end point was the mortality for HBV-ACLF patients. Secondary outcome measures included Model for End-Stage Liver disease (MELD) score, liver biochemical function, coagulation function and complications. Adverse events during treatment were reported.
RESULTS: The mortality was decreased 14.28% in the integrative treatment group compared with WM group (χ(2) =6.156, P=0.013). The integrative treatment was found to signifificantly improve the MELD score (t=2.353, P=0.020). There were statistically signifificant differences in aspartate transaminase, total bilirubin, indirect bilirubin, direct bilirubin and prothrombin time between the two groups (P<0.05 or P<0.01). The complications of ascites (χ(2)=9.033, P=0.003) and spontaneous bacteria peritonitis (χ(2)=4.194, P=0.041) were improved signifificantly in the integrative treatment group. No serious adverse event was reported.
CONCLUSIONS: The integrative treatment of CM and WM was effective and safe for HBV-ACLF patients with cold pattern in CM. The Chinese therapeutic principle "treating cold pattern with hot herbs" remains valuable to the clinical therapy. (Trial registration No. ChiCTR-TRC-10000766).

Entities:  

Keywords:  Chinese medicine; Yinchen Zhufu Decoction; cold pattern; hepatitis B virus-related acute-on-chronic liver failure; mortality

Mesh:

Substances:

Year:  2016        PMID: 27220737     DOI: 10.1007/s11655-016-2582-2

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  30 in total

Review 1.  Acute-on-chronic liver failure: pathophysiological basis of therapeutic options.

Authors:  Rajiv Jalan; Roger Williams
Journal:  Blood Purif       Date:  2002       Impact factor: 2.614

Review 2.  Syndrome differentiation in modern research of traditional Chinese medicine.

Authors:  Miao Jiang; Cheng Lu; Chi Zhang; Jing Yang; Yong Tan; Aiping Lu; Kelvin Chan
Journal:  J Ethnopharmacol       Date:  2012-02-01       Impact factor: 4.360

3.  MELD score as a prognostic model for listing acute liver failure patients for liver transplantation.

Authors:  M B Zaman; E Hoti; A Qasim; D Maguire; P A McCormick; J E Hegarty; J G Geoghegan; O Traynor
Journal:  Transplant Proc       Date:  2006-09       Impact factor: 1.066

Review 4.  Review article: non-biological liver support in liver failure.

Authors:  W Laleman; A Wilmer; P Evenepoel; C Verslype; J Fevery; F Nevens
Journal:  Aliment Pharmacol Ther       Date:  2006-02-01       Impact factor: 8.171

5.  Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Kun Huang; Jin-Hua Hu; Hui-Fen Wang; Wei-Ping He; Jing Chen; Xue-Zhang Duan; Ai-Min Zhang; Xiao-Yan Liu
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

Review 6.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

Review 8.  Artificial liver support systems in the management of complications of cirrhosis.

Authors:  Vanessa Stadlbauer; Nathan A Davies; Sambit Sen; Rajiv Jalan
Journal:  Semin Liver Dis       Date:  2008-02       Impact factor: 6.115

9.  Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval.

Authors:  Qing Liu; Zheng Liu; Tailing Wang; Qingguo Wang; Xiaohong Shi; Wenbin Dao
Journal:  J Gastroenterol Hepatol       Date:  2007-12       Impact factor: 4.029

10.  Identification and pharmacokinetics of multiple constituents in rat plasma after oral administration of Yinchenzhufu decoction.

Authors:  Qian Wang; Peng Jiang; Fu-Yuan Ye; Rong Shi; Yue-Ming Ma; Jie Zhong; Jia-Sheng Wu; Ping Liu; Cheng-Hai Liu; Yi-Qun Jia
Journal:  J Ethnopharmacol       Date:  2014-04-02       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.